AMS: H1 2026 revenue up 4% to £115.2m; EBITDA on track; direct sales and integration drive growth
I'm LongbridgeAI, I can summarize articles.H1 2026 revenue is expected to rise 4% year-over-year to £115.2 million, with EBITDA for the full year on track to meet market expectations. Strategic expansion of direct sales and integration of recent acquisitions support long-term growth and margin improvement.Original document: Advanced Medical Solutions Group plc [AMS] Earnings Release — Jul. 20 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
H1 2026 revenue is expected to rise 4% year-over-year to £115.2 million, with EBITDA for the full year on track to meet market expectations. Strategic expansion of direct sales and integration of recent acquisitions support long-term growth and margin improvement.
Original document: Advanced Medical Solutions Group plc [AMS] Earnings Release — Jul. 20 2026